Search

Your search keyword '"Erinjeri, Joseph P."' showing total 510 results
Start Over Author "Erinjeri, Joseph P."
510 results on '"Erinjeri, Joseph P."'

3. Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.

Author

Kudo, Masatoshi, Chan, Stephen Lam, Sangro, Bruno, Erinjeri, Joseph P., Qin, Shukui, Ren, Zhenggang, Arai, Yasuaki, Breder, Valeriy Vladimirovich, Lin, Shi-Ming, Peron, Jean-Marie, Nguyen, Tien Quang, Yan, Lunan, Chiu, Chang-Fang, Santos, Florinda A., Veluvolu, Anil, Thungappa, Satheesh Chiradoni, Morgan, Claire, Parsons, Kerry, Xynos, Ioannis, and Lencioni, Riccardo

Published
2024
Full Text
View/download PDF

9. A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.

Author

Green, Angela, primary, Zhou, Qin, additional, Iasonos, Alexia, additional, Zammarrelli, William, additional, Weigelt, Britta, additional, Ellenson, Lora H, additional, Chhetri-Long, Rashmi, additional, Shah, Pooja, additional, Hom, Vania, additional, Erinjeri, Joseph P., additional, Petkovska, Iva, additional, Chandarlapaty, Sarat, additional, Cohen, Seth M., additional, Grisham, Rachel N., additional, Konner, Jason A., additional, Rubinstein, Maria M, additional, Tew, William P., additional, Troso-Sandoval, Tiffany A., additional, Aghajanian, Carol, additional, and Makker, Vicky, additional

Published
2024
Full Text
View/download PDF

11. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

Author

D’Angelo, Sandra P., Richards, Allison L., Conley, Anthony P., Woo, Hyung Jun, Dickson, Mark A., Gounder, Mrinal, Kelly, Ciara, Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Rosenbaum, Evan, Chi, Ping, Nacev, Benjamin, Chan, Jason E., Slotkin, Emily K., Kiesler, Hannah, Adamson, Travis, Ling, Lilan, Rao, Pavitra, Patel, Shreyaskumar, Livingston, Jonathan A., Singer, Samuel, Agaram, Narasimhan P., Antonescu, Cristina R., Koff, Andrew, Erinjeri, Joseph P., Hwang, Sinchun, Qin, Li-Xuan, Donoghue, Mark T. A., and Tap, William D.

Published
2022
Full Text
View/download PDF

14. Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy.

Author

Cowzer, Darren, Chou, Joanne F, Walch, Henry, Keane, Fergus, Khalil, Danny, Shia, Jinru, Do, Richard K G, Yarmohammadi, Hooman, Erinjeri, Joseph P, Dika, Imane El, Yaqubie, Amin, Azhari, Hassan, Gambarin, Maya, Hajj, Carla, Crane, Christopher, Wei, Alice C, Jarnagin, William, Solit, David B, Berger, Michael F, and O'Reilly, Eileen M

Subjects
GENOMICS, RESEARCH funding, IMMUNOTHERAPY, HUMAN beings, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, MEDICAL records, ACQUISITION of data, PROGRESSION-free survival, HEPATITIS C, HEPATOCELLULAR carcinoma, PROPORTIONAL hazards models
Abstract

Introduction Immune checkpoint inhibitor (ICI) combinations extend overall survival (OS) while anti-PD-1/L1 monotherapy is non-inferior to sorafenib in treatment-naïve, patients with advanced hepatocellular carcinoma (HCC). Clinicogenomic features are posited to influence patient outcomes. Methods The primary objective of this retrospective study was to define the clinical, pathologic, and genomic factors associated with outcomes to ICI therapy in patients with HCC. Patients with histologically confirmed advanced HCC treated with ICI at Memorial Sloan Kettering Cancer Center from 2012 to 2022 were included. Association between clinical, pathological, and genomic characteristics were assessed with univariable and multivariable Cox regression model for progression-free survival (PFS) and OS. Results Two-hundred and forty-two patients were treated with ICI-based therapy. Patients were predominantly male (82%) with virally mediated HCC (53%) and Child Pugh A score (70%). Median follow-up was 28 months (0.5-78.4). Median PFS for those treated in 1st line, 2nd line and ≥ 3rd line was 4.9 (range: 2.9-6.2), 3.1 (2.3-4.0), and 2.5 (2.1-4.0) months, respectively. Median OS for those treated in 1st line, 2nd line, and ≥ 3rd line was 16 (11-22), 7.5 (6.4-11), and 6.4 (4.6-26) months, respectively. Poor liver function and performance status associated with worse PFS and OS, while viral hepatitis C was associated with favorable outcome. Genetic alterations were not associated with outcomes. Conclusion Clinicopathologic factors were the major determinates of outcomes for patients with advanced HCC treated with ICI. Molecular profiling did not aid in stratification of ICI outcomes. Future studies should explore alternative biomarkers such as the level of immune activation or the pretreatment composition of the immune tumor microenvironment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Adjusted Tumor Enhancement on Dual-Phase Cone-Beam CT: Predictor of Response and Overall Survival in Patients with Liver Malignancies Treated with Hepatic Artery Embolization

Author

Yarmohammadi, Hooman, primary, Ridouani, Fourat, additional, Zhao, Ken, additional, Sotirchos, Vlasios S., additional, Son, Sam Y., additional, Geevarghese, Ruben, additional, Marinelli, Brett, additional, Ghosn, Mario, additional, Erinjeri, Joseph P., additional, Boas, Franz E., additional, and Solomon, Stephen B., additional

Published
2024
Full Text
View/download PDF

18. Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization

Author

Zhao, Ken, primary, Son, Sam, additional, Karimi, Anita, additional, Marinelli, Brett, additional, Erinjeri, Joseph P., additional, Alexander, Erica S., additional, Sotirchos, Vlasios S., additional, Harding, James J., additional, Soares, Kevin C., additional, Ziv, Etay, additional, Covey, Anne, additional, Sofocleous, Constantinos T., additional, and Yarmohammadi, Hooman, additional

Published
2024
Full Text
View/download PDF

21. Current Management of Desmoid Tumors: A Review.

Author

Kasper, Bernd, Baldini, Elizabeth H., Bonvalot, Sylvie, Callegaro, Dario, Cardona, Kenneth, Colombo, Chiara, Corradini, Nadège, Crago, Aimee M., Dei Tos, Angelo P., Dileo, Palma, Elnekave, Eldad, Erinjeri, Joseph P., Navid, Fariba, Farma, Jeffrey M., Ferrari, Andrea, Fiore, Marco, Gladdy, Rebecca A., Gounder, Mrinal, Haas, Rick L., and Husson, Olga

Published
2024
Full Text
View/download PDF

22. Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations

Author

Berning, Philipp, primary, Schroer, Adrian E., additional, Adhikari, Rishav, additional, Razavi, Alexander C., additional, Cornelis, Francois H., additional, Erinjeri, Joseph P., additional, Solomon, Stephen B., additional, Sarkar, Debkumar, additional, Vargas, Hebert Alberto, additional, Schöder, Heiko, additional, Fox, Josef J., additional, and Dzaye, Omar, additional

Published
2024
Full Text
View/download PDF

24. Safety and feasibility of preoperative simultaneous portal vein embolization and biliary drainage in hilar cholangiocarcinoma prior to hepatectomy

Author

Soliman, Mohamed M., primary, Chevallier, Olivier, primary, Velayati, Sara, primary, Zhao, Ken, primary, Marinelli, Brett, primary, Ridouani, Fourat, primary, Karimi, Anita, primary, Covey, Anne, primary, Erinjeri, Joseph P., primary, Schattner, Mark, primary, Harding, James J., primary, Abou-Alfa, Ghassan K., primary, Wei, Alice C., primary, Soares, Kevin C., primary, Jarnagin, William, primary, and Yarmohammadi, Hooman, primary

Published
2024
Full Text
View/download PDF

26. Comparison of periprocedural and procedure room times between moderate sedation and monitored anesthesia care in interventional radiology.

Author

Sotirchos, Vlasios S., Alexander, Erica S., Zhao, Ken, Zhan, Chenyang, Yarmohammadi, Hooman, Ziv, Etay, and Erinjeri, Joseph P.

Subjects
INTERVENTIONAL radiology, LOCAL anesthesia, BEDTIME, ANESTHESIA, TIMESTAMPS, FLUOROSCOPY
Abstract

Objectives: In recent years, there has been increased utilization of monitored anesthesia care (MAC) in interventional radiology (IR) departments. The purpose of this study was to compare pre-procedure bed, procedure room, and post-procedure bed times for IR procedures performed with either nurse-administered moderate sedation (MOSED) or MAC. Material and Methods: An institutional review board-approved single institution retrospective review of IR procedures between January 2010 and September 2022 was performed. Procedures performed with general anesthesia or local anesthetic only, missing time stamps, or where <50 cases were performed for both MAC and MOSED were excluded from the study. Pre-procedure bed, procedure room, post-procedure bed, and total IR encounter times were compared between MAC and MOSED using the t -test. The effect size was estimated using Cohen's d statistic. Results: 97,480 cases spanning 69 procedure codes were examined. Mean time in pre-procedure bed was 27 min longer for MAC procedures (69 vs. 42 min, P < 0.001, d = 0.95). Mean procedure room time was 11 min shorter for MAC (60 vs. 71 min, P < 0.001, d = 0.48), and mean time in post-procedure bed was 10 min longer for MAC (102 vs. 92 min, P < 0.001, d = 0.22). Total IR encounter times were on average 27 min longer for MAC cases (231 vs. 204 min, P < 0.001, d = 0.41). Conclusion: MAC improves the utilization of IR procedure rooms, but at the cost of increased patient time in the pre- and post-procedure areas. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Safety and Efficacy of Hepatic Artery Embolization in Heavily Treated Patients with Intrahepatic Cholangiocarcinoma: Analysis of Clinicopathological and Radiographic Parameters Associated with Better Overall Survival

Author

Velayati, Sara, primary, Elsakka, Ahmed, additional, Zhao, Ken, additional, Erinjeri, Joseph P., additional, Marinelli, Brett, additional, Soliman, Mohamed, additional, Chevallier, Olivier, additional, Ziv, Etay, additional, Brody, Lynn A., additional, Sofocleous, Constantinos T., additional, Solomon, Stephen B., additional, Harding, James J., additional, Abou-Alfa, Ghassan K., additional, D’Angelica, Michael I., additional, Wei, Alice C., additional, Kingham, Peter T., additional, Jarnagin, William R., additional, and Yarmohammadi, Hooman, additional

Published
2023
Full Text
View/download PDF

30. Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

36. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

Author

Lencioni, Riccardo, Kudo, Masatoshi, Erinjeri, Joseph, Qin, Shukui, Ren, Zhenggang, Chan, Stephen, Arai, Yasuaki, Heo, Jeong, Mai, Ahn, Escobar, Jose, Lopez Chuken, Yamil Alonso, Yoon, Jung-Hwan, Tak, Won Young, Suttichaimongkol, Tanita, Bouattour, Mohamed, Lin, Shi-Ming, Żotkiewicz, Magdalena, Udoye, Stephanie, Cohen, Gordon, and Sangro, Bruno

Published
2024
Full Text
View/download PDF

37. Data from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

39. Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

40. A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, additional, Whiting, Karissa A., additional, Richards, Allison L., additional, Avutu, Viswatej, additional, Chan, Jason E., additional, Chi, Ping, additional, Dickson, Mark A., additional, Gounder, Mrinal M., additional, Keohan, Mary Louise., additional, Movva, Sujana, additional, Nacev, Benjamin A., additional, Rosenbaum, Evan, additional, Adamson, Travis, additional, Singer, Samuel, additional, Bartlett, Edmund K., additional, Crago, Aimee M., additional, Yoon, Sam S., additional, Hwang, Sinchun, additional, Erinjeri, Joseph P., additional, Antonescu, Cristina R., additional, Tap, William D., additional, and D'Angelo, Sandra P., additional

Published
2023
Full Text
View/download PDF

45. Prospective Evaluation of Immune Activation Associated with Response to Radioembolization Assessed with PET/CT in Women with Breast Cancer Liver Metastasis

Author

Deipolyi, Amy R., primary, Johnson, C. Bryce, additional, Riedl, Christopher C., additional, Kunin, Henry, additional, Solomon, Stephen B., additional, Oklu, Rahmi, additional, Hsu, Meier, additional, Moskowitz, Chaya S., additional, Kombak, Faruk E., additional, Bhanot, Umesh, additional, and Erinjeri, Joseph P., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results